Cập nhật về liệu pháp kháng kết tập tiểu cầu trong hội chứng mạch vành cấp

Các tác giả

  • Hồ Huỳnh Quang Trí Viện Tim TP. Hồ Chí Minh
  • Nguyễn Lân Việt Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai

Tóm tắt

Cập nhật về liệu pháp kháng kết tập tiểu cầu trong hội chứng mạch vành cấp

Tài liệu tham khảo

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;332:349-360.

2. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-1672.

3. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.

4. Sabatine MS, Cannon CP, Gibson CM, et al, for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST elevation. N Engl J Med 2005;352:1179-1189

5. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45.852 patients with acute myocardial infarction: randomised placebo- controlled trial. Lancet 2005;366:1607-1621.

6. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008;117:296- 329.

7. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction - Executive summary. J Am Coll Cardiol 2007;50:652-726.

8. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.

9. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: Benefits and limitations. Am Heart J 2008;156:S3-S9.

10. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am JCardiol 2009;103[suppl]:27A- 34A.

11. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-2436.

12. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-317.

13. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362.

14. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. The randomised, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260.

15. Bhatt DL, Cryer BL, Contant CF, et al, for the COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-1917.

16. The FDA safety information and adverse event reporting program. www.fda.gov/Safety/MedWatch/ SafetyInformation/ucm225843.htm.

17. Collet JP, Cuisset T, Rangé G, et al, for the ARCTIC Investigators. Bedside monitoring to adjust antiplatelet

therapy for coronary stenting. N Engl J Med 2012;367:2100-2109.

18. The CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-942.

19. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA Focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2012;126:875- 910.

20. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST- elevation myocardial infarction. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-e140.

21. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010;122:394-403.

22. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735- 741.

23. Wiviott SD, Braunwald E, McCabe CH, et al, for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.

24. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-1856.

25. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047.

26. Wallentin L, Becker RC, Budaj A, et al, for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.

27. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011;124:544-554.

28. Cannon CP, Harrington RA, James S, et al, for the PLATO Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-293.

29. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLAtelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:d3527 doi:10.1136/bmj.d3527

Tải xuống

Đã Xuất bản

01-11-2014

Cách trích dẫn

Hồ Huỳnh Quang Trí, & Nguyễn Lân Việt. (2014). Cập nhật về liệu pháp kháng kết tập tiểu cầu trong hội chứng mạch vành cấp. Tạp Chí Tim mạch học Việt Nam, (68), 291–300. Truy vấn từ https://jvc.vnha.org.vn/tmh/article/view/652

Số

Chuyên mục

CHUYÊN ĐỀ

Các bài báo được đọc nhiều nhất của cùng tác giả

1 2 3 4 5 > >>